+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2017-05-10Number of Pages: 157

Cancer Biomarkers Market (Test Type - PSA Tests, CTC Tests, AFP Tests, CA Tests, HER2 Tests, BRCA Tests, ALK Tests, CEA Tests, EGFR Mutation Tests, and KRAS Mutation Tests; Disease Indication - Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma, Blood Cancer, Prostate Cancer, Ovarian Cancer, Stomach Cancer, and Liver Cancer) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

Global Cancer Biomarkers Market: Snapshot

Cancer is a complex and potentially fatal disease that is primarily caused through environmental factors resulting in gene mutations affecting critical cell-regulatory proteins. These factors may act together or in a sequence to trigger tumor formation. Rising incidences of cancer and increasing healthcare expenditure are expected to aid the global cancer biomarkers market. The global market for cancer biomarkers is expected to grow at an exponential rate benefiting from the recent advances in technology, favorable government initiatives and funding.

Moreover, the development in companion diagnostics and recent breakthrough in detection techniques such as proteomics, metabolomics, genomics and transcriptomics are further expected to boost the demand for cancer biomarkers. Cancer biomarker is critical in improving early detection and treatment of any cancer type. Awareness and screening for cancer have increased over the last couple of decades resulting in early diagnosis of cancer and subsequent reduction of mortality. However, the ultimate goal of reducing mortality in late-stage cancer has not been satisfactorily achieved.

Besides this, the cancer biomarkers market is expected to gain from the rising geriatric population, increasing incidences of cancer, and increasing prevalence of tumor. Technological advancements in the field of biomarkers resulting in new and innovative products have increased the safety, improved efficacy and reduced the side effects. Spurred by these factors, the global cancer biomarkers market is forecast to exhibit a CAGR of 11.8% between 2017 and 2025. At this pace, the market is expected to reach US$27.63 bn by the end of 2025 from US$10.25 bn in 2016.

cancer biomarkers market

Lung Cancer Emerges as Leading Segment Based on Disease Indication

The CTC tests segment by test type accounted the largest share of the global cancer biomarkers market in 2016, and is expected to dominate the market during the forecast period from 2017 to 2025. Factors such as increase in prevalence of the various types of tumor and increasing incidences of cancer related to the vital organs drives the CTC tests segment. Although associated with non-drivers of selection, such as quick and easy order processing and availability from a contracted manufacturer, the cancer biomarkers market presents immense competition for new market players.

The lung cancer segment in terms of disease indication has the largest market share of the global cancer biomarkers market in 2016, and is expected to grow during the forecast period due to increasing prevalence of lung cancer in developing countries, growing cigarette smoking among the population, rising geriatric population, and technological advancements with regard to lesser side effects associated with biomarkers test and early detection of the illness drive demand for lung cancer diagnosis globally.

North America to Remain Dominant Regional Market through Forecast Period

North America dominated the global cancer biomarkers market in 2016 and is expected to remain dominant through the forecast period. This is due to high prevalence of cancer, increasing health care expenditure leading to increase in demand for better diagnostic tests and health care services, and number of technological advancements in the field of cancer biomarkers. However, the market in Asia Pacific is projected to register a significant growth rate by 2025 due to availability of large patient pool and increasing awareness about health. In addition, high percentage of geriatric population, and increasing disposable income are expected to propel the market.

Major players operating in the global cancer biomarkers market include Abbott Laboratories, Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Illumina, Inc., Agilent Technologies, QIAGEN, Merck & Co., Inc., Hologic, Inc., Novartis AG, bioMérieux SA, Genomic Health, Inc., are among others.

1. Preface

2. Research Methodology & Assumptions

3. Executive Summary

4. Global Cancer Biomarkers Products Market Overview
     4.1 Introduction (Product Definition)
     4.2 Industry Evolution/Development 
     4.3 Key Market Indicators
     4.4 Market Dynamics
          4.4.1 Drivers
          4.4.2 Restraints
          4.4.3 Opportunity
     4.5  Global Cancer Biomarkers Market Analysis and Forecasts, 2015 – 2025
     4.6 Cancer Biomarkers Market - Global Supply Demand Scenario
     4.7 Porter’s Five Force Analysis
     4.8 Market Outlook
     4.9 Cancer Epidemiology, by region

5. Global Cancer Biomarkers Market Analysis and Forecast by Test Type
     5.1 Key Findings
     5.2 Introduction
     5.3 Market Size (US$ Mn) Forecast, By Test Type
          5.3.1 PSA Tests
          5.3.2 CTC Tests
          5.3.3 AFP Tests
          5.3.4 CA Tests
          5.3.5 HER2 Tests
          5.3.6 BRCA Tests
          5.3.7 ALK Tests
          5.3.8 CEA Tests
          5.3.9 EGFR Mutation Tests
          5.3.10 KRAS Mutation Tests
          5.3.11 Others 
     5.4 Market Attractiveness, By Test Type
     5.5 Key Trends

6. Global Cancer Biomarkers Market Analysis and Forecast by Disease Indication
     6.1 Key Findings
     6.2 Introduction
     6.3 Market Size (US$ Mn) Forecast, By Disease Indication
          6.3.1 Breast Cancer
          6.3.2 Lung Cancer
          6.3.3 Colorectal Cancer
          6.3.4 Melanoma
          6.3.5 Blood Cancer
          6.3.6 Prostate Cancer
          6.3.7 Ovarian Cancer
          6.3.8 Stomach Cancer
          6.3.9 Liver Cancer
          6.3.10 Others
     6.4 Market Attractiveness, By Disease Indication
     6.5 Key Trends

7. Global Cancer Biomarkers Market Analysis and Forecast by Region
     7.1 Key Findings
     7.2 Introduction
          7.2.1 Market Size (US$ Mn) Forecast, By Region
          7.2.2 North America
          7.2.3 Europe
          7.2.4 Asia Pacific
          7.2.5 Latin America
          7.2.6 Middle East and Africa

8. North America Cancer Biomarkers Market Analysis and Forecast by Region
     8.1 Key Findings
     8.2 North America Cancer Biomarkers Market Forecast, by Test Type
     8.3 North America Cancer Biomarkers Market Forecast, by Disease Indication     
     8.4 North America Cancer Biomarkers Market Forecast, by Country
          8.4.1 U.S. Cancer Biomarkers Market Overview
          8.4.2 Canada Cancer Biomarkers Market Overview
     8.5 North America Market Attractiveness Analysis
     8.6 Market Trends

9.  Europe Cancer Biomarkers Market Analysis and Forecast by Region
     9.1 Key Findings
     9.2 Europe Cancer Biomarkers Market Forecast, by Test Type
     9.3 Europe Cancer Biomarkers Market Forecast, by Disease Indication
     9.4 Europe Cancer Biomarkers Market Forecast, by Country
          9.4.1 U.K. Cancer Biomarkers Market Overview
          9.4.2 Germany Cancer Biomarkers Market Overview
          9.4.3 France Cancer Biomarkers Market Overview
          9.4.4 Italy Cancer Biomarkers Market Overview
          9.4.5 Spain Cancer Biomarkers Market Overview
          9.4.6 Russia Cancer Biomarkers Market Overview
          9.4.7 Rest of Europe Cancer Biomarkers Market Overview
     9.5 Europe Market Attractiveness Analysis
     9.6 Market Trends

10.  Asia Pacific Cancer Biomarkers Market Analysis and Forecast by Region
     10.1 Key Findings
     10.2 Asia Pacific Cancer Biomarkers Market Forecast, by Test Type
     10.3 Asia Pacific Cancer Biomarkers Market Forecast, by Disease Indication
     10.4 Asia Pacific Cancer Biomarkers Market Forecast, by Country
          10.4.1 India Cancer Biomarkers Market Overview
          10.4.2 China Cancer Biomarkers Market Overview
          10.4.3 Japan Cancer Biomarkers Market Overview
          10.4.4 Australia & New Zealand Cancer Biomarkers Market Overview
          10.4.5 Rest of APAC Cancer Biomarkers Market Overview
     10.5 Asia Pacific Market Attractiveness Analysis
     10.6 Market Trends

11. Latin America Cancer Biomarkers Market Analysis and Forecast by Region
     11.1 Key Findings
     11.2 Latin America Cancer Biomarkers Market Forecast, by Test Type
     11.3 Latin America Cancer Biomarkers Market Forecast, by Disease Indication
     11.4 Latin America Cancer Biomarkers Market Forecast, by Country
          11.4.1 Brazil Cancer Biomarkers Market Overview
          11.4.2 Mexico Cancer Biomarkers Market Overview
          11.4.3 Rest of LATAM Cancer Biomarkers Market Overview
     11.5 Latin America Market Attractiveness Analysis
     11.6 Market Trends

12. Middle East and Africa Cancer Biomarkers Market Analysis and Forecast by Region
     12.1 Key Findings
     12.2 Middle East and Africa Cancer Biomarkers Market Forecast, by Test Type
     12.3 Middle East and Africa Cancer Biomarkers Market Forecast, by Disease Indication
     12.4 Middle East and Africa Cancer Biomarkers Market Forecast, by Country
          12.4.1 South Africa Cancer Biomarkers Market Overview
          12.4.2 GCC countries Cancer Biomarkers Market Overview
          12.4.3 Rest of MEA Cancer Biomarkers Market Overview
     12.5 Middle East and Africa Market Attractiveness Analysis
     12.6 Market Trends

13.  Competitive Landscape
     13.1 Market Share Analysis, by Company
     13.2 Competition Matrix
     13.3 Company Profiles
          13.3.1 Abbott Laboratories
                   13.3.1.1 Company Details
                   13.3.1.2 Business Overview
                   13.3.1.3 Financial Overview
                   13.3.1.4 Strategic Overview
                   13.3.1.5 SWOT Analysis
          13.3.2 Merck & Co., Inc.
                   13.3.2.1 Company Details
                   13.3.2.2 Business Overview
                   13.3.2.3 Financial Overview
                   13.3.2.4 Strategic Overview
                   13.3.2.5 SWOT Analysis
          13.3.3 Thermo Fisher Scientific Inc
                   13.3.3.1 Company Details
                   13.3.3.2 Business Overview
                   13.3.3.3 Financial Overview
                   13.3.3.4 Strategic Overview
                   13.3.3.5 SWOT Analysis
          13.3.4 Illumina, Inc.
                   13.3.4.1 Company Details
                   13.3.4.2 Business Overview
                   13.3.4.3 Financial Overview
                   13.3.4.4 Strategic Overview
                   13.3.4.5 SWOT Analysis
          13.3.5 bioMérieux SA
                   13.3.5.1 Company Details
                   13.3.5.2 Business Overview
                   13.3.5.3 Financial Overview
                   13.3.5.4 Strategic Overview
                   13.3.5.5 SWOT Analysis
          13.3.6 QIAGEN
                   13.3.6.1 Company Details
                   13.3.6.2 Business Overview
                   13.3.6.3 Financial Overview
                   13.3.6.4 Strategic Overview
                   13.3.6.5 SWOT Analysis
          13.3.7 Agilent Technologies, Inc.
                   13.3.7.1 Company Details
                   13.3.7.2 Business Overview
                   13.3.7.3 Financial Overview
                   13.3.7.4 Strategic Overview
                   13.3.7.5 SWOT Analysis
          13.3.8 Hologic, Inc.
                   13.3.8.1 Company Details
                   13.3.8.2 Business Overview
                   13.3.8.3 Financial Overview
                   13.3.8.4 Strategic Overview
                   13.3.8.5 SWOT Analysis
          13.3.9 Novartis AG
                   13.3.9.1 Company Details
                   13.3.9.2 Business Overview
                   13.3.9.3 Financial Overview
                   13.3.9.4 Strategic Overview
                   13.3.9.5 SWOT Analysis
          13.3.10 F. Hoffmann-La Roche Ltd.
                   13.3.10.1 Company Details
                   13.3.10.2 Business Overview
                   13.3.10.3 Financial Overview
                   13.3.10.4 Strategic Overview
                   13.3.10.5 SWOT Analysis
          13.3.11 Genomic Health, Inc.
                   13.3.11.1 Company Details
                   13.3.11.2 Business Overview
                   13.3.11.3 Financial Overview
                   13.3.11.4 Strategic Overview
                   13.3.11.5 SWOT Analysis

List of Figures

Figure 01: Global Cancer Biomarkers Market Size (US$ Mn) Forecast, 2016 – 2025
Figure 02: Global Cancer Biomarkers Market Value Share Analysis By Test Type, 2017 and 2025
Figure 03: Global Cancer Biomarkers Test Types Market Revenue (US$ Mn) and Y-o-Y Growth (%), by PSA Tests, 2016-2025
Figure 04: Global Cancer Biomarkers Test Types Market Revenue (US$ Mn) and Y-o-Y Growth (%), by CTC Tests, 2016-2025
Figure 05: Global Cancer Biomarkers Test Types Market Revenue (US$ Mn) and Y-o-Y Growth (%), by AFP Tests, 2016-2025
Figure 06: Global Cancer Biomarkers Test Types Market Revenue (US$ Mn) and Y-o-Y Growth (%), by CA Tests, 2016-2025
Figure 07: Global Cancer Biomarkers Test Types Market Revenue (US$ Mn) and Y-o-Y Growth (%), by HER2 Tests, 2016-2025
Figure 08: Global Cancer Biomarkers Test Types Market Revenue (US$ Mn) and Y-o-Y Growth (%), by BRCA Tests, 2016-2025
Figure 09: Global Cancer Biomarkers Test Types Market Revenue (US$ Mn) and Y-o-Y Growth (%), by ALK Tests, 2016-2025
Figure 10: Global Cancer Biomarkers Test Types Market Revenue (US$ Mn) and Y-o-Y Growth (%), by CEA Tests, 2016-2025
Figure 11: Global Cancer Biomarkers Test Types Market Revenue (US$ Mn) and Y-o-Y Growth (%), by EGFR Tests, 2016-2025
Figure 12: Global Cancer Biomarkers Test Types Market Revenue (US$ Mn) and Y-o-Y Growth (%), by KRAS Mutation Tests, 2016-2025
Figure 13: Global Cancer Biomarkers Test Types Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2016-2025
Figure 14: Cancer Biomarkers Market Attractiveness Analysis By Test Type
Figure 15: Global Cancer Biomarkers Market Value Share Analysis By Disease Indication, 2017 and 2025
Figure 16: Global Cancer Biomarkers Test Types Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Breast Cancer, 2016-2025
Figure 17: Global Cancer Biomarkers Test Types Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Lung Cancer, 2016-2025
Figure 18: Global Cancer Biomarkers Test Types Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Colorectal Cancer, 2016-2025
Figure 19: Global Cancer Biomarkers Test Types Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Melanoma, 2016-2025
Figure 20: Global Cancer Biomarkers Test Types Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Blood Cancer, 2016-2025
Figure 21: Global Cancer Biomarkers Test Types Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Prostate Cancer, 2016-2025
Figure 22: Global Cancer Biomarkers Test Types Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Ovarian Cancer, 2016-2025
Figure 23: Global Cancer Biomarkers Test Types Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Stomach Cancer, 2016-2025
Figure 24: Global Cancer Biomarkers Test Types Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Liver Cancer, 2016-2025
Figure 25: Global Cancer Biomarkers Test Types Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2016-2025
Figure 26: Cancer Biomarkers Market Attractiveness Analysis By Disease Indication
Figure 27: Global Cancer Biomarkers Market Value Share Analysis By Region Type, 2017 and 2025
Figure 28: Cancer Biomarkers Market Attractiveness Analysis, By Region Type
Figure 29: North America Cancer Biomarkers Market Size (US$ Mn) Forecast, 2017 – 2025
Figure 30: North America Market Attractiveness Analysis By Country
Figure 31: North America Cancer Biomarkers Market Value Share Analysis By Test Type, 2017 and 2025
Figure 32: North America Cancer Biomarkers Market Value Share Analysis By Disease Indication, 2017 and 2025
Figure 33: North America Market Value Share Analysis By Country, 2017 and 2025
Figure 34: North America Market Attractiveness Analysis, By Test Type
Figure 35: North America Market Attractiveness Analysis, By Disease Indication
Figure 36: Europe Cancer Biomarkers Market Size (US$ Mn) Forecast, 2016 – 2025
Figure 37: Europe Market Attractiveness Analysis By Country
Figure 38: Europe Cancer Biomarkers Market Value Share Analysis By Test Type, 2017 and 2025
Figure 39: Europe Cancer Biomarkers Market Value Share Analysis By Disease Indication, 2017 and 2025
Figure 40: Europe Market Value Share Analysis By Country, 2017 and 2025
Figure 41: Europe Market Attractiveness Analysis, By Test Type
Figure 42: Europe Market Attractiveness Analysis, By Disease Indication
Figure 43: Asia Pacific Cancer Biomarkers Market Size (US$ Mn) Forecast, 2016 – 2025
Figure 44: Asia Pacific Market Attractiveness Analysis By Country
Figure 45: Asia Pacific Cancer Biomarkers Market Value Share Analysis By Test Type, 2017 and 2025
Figure 46: Asia Pacific Cancer Biomarkers Market Value Share Analysis By Disease Indication, 2017 and 2025
Figure 47: Europe Market Value Share Analysis By Country, 2017 and 2025
Figure 48: Asia Pacific Market Attractiveness Analysis, By Test Type
Figure 49: Asia Pacific Market Attractiveness Analysis, By Disease Indication
Figure 50: Latin America Cancer Biomarkers Market Size (US$ Mn) Forecast, 2016 – 2025
Figure 51: Latin America Market Attractiveness Analysis By Country
Figure 52: Latin America Cancer Biomarkers Market Value Share Analysis By Test Type, 2017 and 2025
Figure 53: Latin America Cancer Biomarkers Market Value Share Analysis By Disease Indication, 2017 and 2025
Figure 54: Latin America Market Value Share Analysis By Country, 2017 and 2025
Figure 55: Latin America Market Attractiveness Analysis, By Test Type
Figure 56: Latin America Market Attractiveness Analysis, By Disease Indication
Figure 57: Middle East & Africa Cancer Biomarkers Market Size (US$ Mn) Forecast, 2016 – 2025
Figure 58: Middle East & Africa Market Attractiveness Analysis By Country
Figure 59: Middle East & Africa Cancer Biomarkers Market Value Share Analysis By Test Type, 2017 and 2025
Figure 60: Middle East & Africa Cancer Biomarkers Market Value Share Analysis By Disease Indication, 2017 and 2025
Figure 61: Middle East & Africa Market Value Share Analysis By Country, 2017 and 2025
Figure 62: Middle East & Africa Market Attractiveness Analysis, By Test Type
Figure 63: Middle East & Africa Market Attractiveness Analysis, By Disease Indication
Figure 64: Global Cancer Biomarkers Market Share Analysis By Company (2015)

List of Table

Table 01: Global Cancer Biomarkers Market Size (US$ Mn) Forecast, By Test Type, 2015–2025
Table 02: Global Cancer Biomarkers Market Size (US$ Mn) Forecast, By Disease Indication, 2015–2025
Table 03: Global Cancer Biomarkers Market Size (US$ Mn) Forecast, By Region Type, 2015 – 2025
Table 04: North America Cancer Biomarkers Market Size (US$ Mn) Forecast, By Test Type, 2015–2025
Table 05: North America Cancer Biomarkers Market Size (US$ Mn) Forecast, By Disease Indication, 2015–2025
Table 06: North America Cancer Biomarkers Market Size (US$ Mn) Forecast, By Country, 2015–2025
Table 07: Europe Cancer Biomarkers Market Size (US$ Mn) Forecast, By Test Type, 2015–2025
Table 08: Europe Cancer Biomarkers Market Size (US$ Mn) Forecast, By Disease Indication, 2015–2025
Table 09: Europe Cancer Biomarkers Market Size (US$ Mn) Forecast, By Country, 2015–2025
Table 10: Asia Pacific Cancer Biomarkers Market Size (US$ Mn) Forecast, By Test Type, 2015–2025
Table 11: Asia Pacific Cancer Biomarkers Market Size (US$ Mn) Forecast, By Disease Indication, 2015–2025
Table 12: Asia Pacific Cancer Biomarkers Market Size (US$ Mn) Forecast, By Country, 2015–2025
Table 13: Latin America Cancer Biomarkers Market Size (US$ Mn) Forecast, By Test Type, 2015–2025
Table 14: Latin America Cancer Biomarkers Market Size (US$ Mn) Forecast, By Disease Indication, 2015–2025
Table 15: Latin America Cancer Biomarkers Market Size (US$ Mn) Forecast, By Country, 2015–2025
Table 16: Middle East & Africa Cancer Biomarkers Market Size (US$ Mn) Forecast, By Test Type, 2015–2025
Table 17: Middle East & Africa Cancer Biomarkers Market Size (US$ Mn) Forecast, By Disease Indication, 2015–2025
Table 18: Middle East & Africa Cancer Biomarkers Market Size (US$ Mn) Forecast, By Country, 2015–2025

Global Cancer Biomarkers Market: Overview  

Biomarkers are the substance or molecules found in blood, other body fluids or tissues which states the normal and abnormal condition of the body, biomarkers helps to detect various diseases such as cancer. Cancer biomarkers tests are carried out to detect genes or mutated genes responsible for cancer. Dramatic improvement in the cancer biomarkers tests will increase demand globally.

A detailed overview of market dynamics, including the drivers, restraints, and opportunities of the cancer biomarkers market, has been provided in this report. Market revenue for all the above mentioned segments, and their sub segments has been provided for the forecast period of 2017-2025, considering 2016 as the base year, and 2015 as the historical year, along with compound annual growth rate (CAGR %), for the forecast period of 2017-2025. Market share estimations were based on in-depth analysis and study of products, and their features, prices etc.

This report provides in-depth analysis of the cancer biomarkers market. The stakeholders for this report include companies involved in the reagent manufacturer for cancer biomarkers tests. For providing a snapshot of this market to the stakeholders, executive summary section is included in this report, which summarizes the market size, trends and competition in different regions. Market share analysis among the market players is analyzed to signify percentage share of the major players operating in the cancer biomarkers market. Furthermore, the report incorporates market attractiveness analysis by geography that depicts the most attractive and significant region in the global market in 2015.

The research methodology is a combination of primary and secondary research. Primary research includes information collected via e-mails, and telephonic interviews of Key Opinion Leaders (KOL), and forms the bulk of our research. Secondary research includes information collected from various sources, by study of company websites, annual reports, stock analysis presentations, press releases, and various national and international databases.  

Global Cancer Biomarkers Market: Segmentation

Based on test type, global cancer biomarkers market are segmented into PSA tests, CTC tests, AFP tests, CA tests, HER2 tests, BRCA tests, ALK tests, CEA tests, EGFR Mutation tests, KRAS Mutation tests and others. Based on disease indication, the cancer biomarkers market are segmented into breast cancer, lung cancer, colorectal cancer, melanoma, blood cancer, prostate cancer, ovarian cancer, stomach cancer, liver cancer and others.

Based on geography, the cancer biomarkers market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. The regions are further segmented into major countries which include, U.S., Canada, Germany, U.K., France, Spain, Italy, Russia, rest of Europe, India, China, Japan, Australia and New Zealand, Rest of Asia Pacific, Brazil, Mexico, Rest of Latin America, GCC countries, South Africa and Rest of Middle East and Africa.

Companies Mentioned in the Report

The report also comprises list major players in the market, their SWOT analysis, market share of these players in the cancer biomarkers, key business strategies, product portfolios, and recent developments. Key market players profiled in this report include, Abbott Laboratories, Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Illumina, Inc., Agilent Technologies, QIAGEN, Merck & Co., Inc., Hologic, Inc., Novartis AG, bioMérieux SA, Genomic Health, Inc. and others

The global cancer biomarkers market has been segmented as follows:

  • Global Cancer Biomarkers Market, by Test Type
    • PSA Tests
    • CTC Tests
    • AFP Tests
    • CA Tests
    • HER2 Tests
    • BRCA Tests
    • ALK Tests
    • CEA Tests
    • EGFR Mutation Tests
    • KRAS Mutation Tests
    • Others
       
  • Global Cancer Biomarkers Market, by Disease Indication
    • Breast Cancer
    • Lung Cancer
    • Colorectal Cancer
    • Melanoma
    • Blood Cancer
    • Prostate Cancer
    • Ovarian Cancer
    • Stomach Cancer
    • Liver Cancer
    • Others
       
  • Global Cancer Biomarkers Market, by Geography
    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • France
      • U.K.
      • Spain
      • Italy
      • Rest of Europe
    • Asia Pacific
      • India
      • China
      • Japan
      • Australia & New Zealand
      • Rest of Asia Pacific
    • Latin America
      • Brazil
      • Mexico
      • Rest of Latin America
    • Middle East and Africa
      • GCC countries
      • South Africa
      • Rest of MEA


 
 
Back To Top